The Manufacturers Life Insurance Company Reduces Stock Position in Align Technology, Inc. $ALGN

The Manufacturers Life Insurance Company reduced its stake in Align Technology, Inc. (NASDAQ:ALGN) by 2.9% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 273,926 shares of the medical equipment provider’s stock after selling 8,088 shares during the period. The Manufacturers Life Insurance Company’s holdings in Align Technology were worth $46,959,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in ALGN. Capital International Investors lifted its holdings in Align Technology by 52.2% during the 4th quarter. Capital International Investors now owns 4,643,221 shares of the medical equipment provider’s stock worth $725,039,000 after purchasing an additional 1,592,848 shares in the last quarter. Ruane Cunniff & Goldfarb L.P. bought a new position in Align Technology in the 4th quarter worth about $190,899,000. Norges Bank purchased a new position in Align Technology during the 4th quarter valued at about $155,556,000. Assenagon Asset Management S.A. grew its holdings in Align Technology by 413.0% during the 1st quarter. Assenagon Asset Management S.A. now owns 989,388 shares of the medical equipment provider’s stock valued at $169,611,000 after buying an additional 796,529 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its position in shares of Align Technology by 247.3% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,005,413 shares of the medical equipment provider’s stock valued at $156,995,000 after buying an additional 715,919 shares during the period. 88.43% of the stock is currently owned by hedge funds and other institutional investors.

More Align Technology News

Here are the key news stories impacting Align Technology this week:

• Positive Sentiment: Q2 results exceeded expectations: Align reported adjusted earnings of $2.64 per share versus the $2.62 consensus estimate, while revenue reached approximately $1.06 billion, ahead of expectations and up 4.3% year over year. Non-GAAP margins also improved. Align Technology Announces Second Quarter 2026 Financial Results
• Positive Sentiment: Clear-aligner momentum remains strong: Record Invisalign shipments and continued expansion of digital workflows support Align’s core growth strategy. Management highlighted increased adoption of connected orthodontic tools and reaffirmed its 2026 outlook. ALGN Q2 Earnings Call Highlights Digital Growth Push
• Positive Sentiment: Board and strategic changes could enhance shareholder value: Align plans to add three independent directors and conduct an operational review following discussions with Elliott Investment Management. The initiatives may improve governance, efficiency and capital allocation. Align Technology to overhaul board following engagement with Elliott
• Neutral Sentiment: Digital orthodontics remains a long-term focus: At its 2026 Invisalign Ortho Summit, Align presented its “Beyond Possible” vision for connected digital orthodontics, emphasizing integration of Invisalign, iTero scanners and exocad software. The event reinforces the company’s strategy but provides limited immediate financial impact. Align Technology Hosts 2026 Invisalign Ortho Summit
• Negative Sentiment: Near-term concerns temper the earnings beat: Third-quarter revenue guidance was broadly in line but was viewed as slightly below some expectations. Investors are also monitoring scanner pricing pressure and weaker systems performance, which could limit revenue growth and offset clear-aligner strength. Needham maintained a Hold rating, citing capped near-term upside. Align Technology Hold Rating Maintained

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on ALGN shares. Leerink Partners increased their price target on shares of Align Technology from $225.00 to $230.00 in a report on Thursday, April 30th. Citigroup began coverage on shares of Align Technology in a research note on Wednesday, April 15th. They set a “buy” rating and a $240.00 price objective for the company. BMO Capital Markets initiated coverage on shares of Align Technology in a report on Wednesday, July 8th. They set an “outperform” rating and a $209.00 target price on the stock. UBS Group reiterated a “neutral” rating and issued a $189.00 target price on shares of Align Technology in a research note on Thursday, July 23rd. Finally, Zacks Research downgraded shares of Align Technology from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 16th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, Align Technology presently has an average rating of “Moderate Buy” and a consensus target price of $206.36.

Align Technology Trading Down 3.7%

ALGN stock opened at $173.41 on Friday. The company’s 50 day moving average is $174.44 and its 200 day moving average is $175.25. The stock has a market cap of $12.42 billion, a price-to-earnings ratio of 30.16, a price-to-earnings-growth ratio of 1.85 and a beta of 1.67. Align Technology, Inc. has a 1-year low of $122.00 and a 1-year high of $200.43.

Align Technology (NASDAQ:ALGN) last announced its earnings results on Wednesday, July 29th. The medical equipment provider reported $2.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.62 by $0.02. Align Technology had a net margin of 9.99% and a return on equity of 16.04%. The business had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.05 billion. During the same period in the previous year, the business posted $2.49 earnings per share. Align Technology’s revenue for the quarter was up 4.3% on a year-over-year basis. As a group, sell-side analysts forecast that Align Technology, Inc. will post 9.48 EPS for the current fiscal year.

Align Technology declared that its Board of Directors has initiated a stock repurchase program on Wednesday, April 29th that authorizes the company to repurchase $200.00 million in shares. This repurchase authorization authorizes the medical equipment provider to purchase up to 1.6% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board believes its shares are undervalued.

Align Technology Profile

Align Technology, Inc (NASDAQ: ALGN) pioneered the use of digital technology in orthodontics through the development of the Invisalign system, a series of clear, removable aligners that provide an alternative to traditional metal braces. Since its founding in 1997 by Zia Chishti and Kelsey Wirth, the Tempe, Arizona–based company has expanded its focus to include intraoral scanners, CAD/CAM software for dental laboratories and comprehensive digital dentistry solutions.

The company’s signature Invisalign system leverages 3D imaging and computer-aided design (CAD) to create customized aligners that gradually reposition teeth, improving patient comfort and treatment predictability.